Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jun 30 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding its final approval from the USFDA for Lacosamide Injection. This injection is intended for treating partial-onset seizures and primary generalized tonic-clonic seizures. The product will be manufactured at the company's facility in Jarod, India, and has a significant market size.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases